Isolation of human intestinal bacteria capable of producing the bioactive metabolite isourolithin a from ellagic acid

Frontiers in Microbiology

Volumn 8, Issue AUG, 2017, Pages

  Selma, María V ^a   Beltrán, David ^a   Luna, María C ^a   Romo Vaquero, María ^a   García Villalba, Rocío ^a   Mira, Alex ^b   Espín, Juan C ^a   Tomás Barberán, Francisco A ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

^b FISABIO   (Spain)

Author keywords

Bioconversion; Ellagitannin; Gut bacteria; Metabotype; Novel probiotic; Polyphenols; Urolithin

Indexed keywords

DRUG METABOLITE; ELLAGIC ACID; ELLAGITANNIN; RNA 16S; UNCLASSIFIED DRUG; UROLITHIN C;

ADULT; ARTICLE; BACTERIAL GROWTH; CATABOLISM; CORRELATION ANALYSIS; FECES ANALYSIS; GENE SEQUENCE; HUMAN; INTESTINE FLORA; ISOLATION PROCEDURE; MALE; METABOLIC ACTIVITY ASSAY; NONHUMAN; NORMAL HUMAN; PHOTODIODE ARRAY DETECTOR; PHYLOGENETIC TREE; POMEGRANATE; QUADRUPOLE MASS SPECTROMETRY; RNA GENE; STRAWBERRY; URINALYSIS; WALNUT;

EID: 85027222424     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.01521     Document Type: Article

References (33)

1. Arahal, D. R., Sánchez, E., Macián, M. C., and Garay, E. (2008). Value of recN sequences for species identification and as a phylogenetic marker within the family "Leuconostocaceae". Int. Microbiol. 11, 33-39. doi: 10.2436/20.1501. 01.42
2. Baranyi, J., Roberts, T. A., and McClure, P. (1993). A non-autonomous different equation to model bacterial growth. Food Microbiol. 10, 43-59. doi: 10.1006/ fmic.1993.1005
3. Braune, A., and Blaut, M. (2016). Bacterial species involved in the conversion of dietary flavonoids in the human gut. Gut Microbes 7, 1-19. doi: 10.1080/ 19490976.2016.1158395
4. Cerdá, B., Espín, J. C., Parra, S., Martínez, P., and Tomás-Barberán, F. A. (2004). The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur. J. Nutr. 43, 205-220. doi: 10.1007/s00394-004-0461-7
5. Craney, A., Ahmed, S., and Nodwell, J. (2013). Towards a new science of secondary metabolism. J. Antibiot. 66, 387-400. doi: 10.1038/ja.2013.25
6. Derrien, M., Belzer, C., and de Vos, W. M. (2016). Akkermansia muciniphila and its role in regulating host functions.Microb. Pathog. 106, 171-181. doi: 10.1016/ j.micpath.2016.02.005
7. Eppinga, H., Weiland, C. J. S., Thio, H. B., van der Woude, C. J., Nijsten, T. E., Peppelenbosch, M. P., et al. (2016). Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J. Crohns. Colitis. 10, 1067-1075. doi: 10.1093/ ecco-jcc/jjw070
8. Espín, J. C., González-Sarrías, A., and Tomás-Barberán, F. A. (2017). The gut microbiota: a key factor in the therapeutic effects of (poly)phenols. Biochem. Pharmacol. 17, 30252-30256. doi: 10.1016/j.bcp.2017.04.033
9. Espín, J. C., Larrosa, M., García-Conesa, M. T., and Tomás-Barberán, F. (2013). Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. Evid. Based Complement. Alternat. Med. 2013:270418. doi: 10.1155/2013/270418
10. Fournier, P.-E., Rossi-Tamisier, M., Benamar, S., and Raoult, D. (2015). Cautionary tale of using 16S rRNA gene sequence similarity values in identification of human-associated bacterial species. Int. J. Syst. Evol. Microbiol. 65, 1929-1934. doi: 10.1099/ijs.0.000161
11. García-Villalba, R., Beltrán, D., Espín, J. C., Selma, M. V., and Tomás-Barberán, F. A. (2013). Time course production of urolithins from ellagic acid by human gut microbiota. J. Agric. Food Chem. 61, 8797-8806. doi: 10.1021/jf402498b
12. García-Villalba, R., Espín, J. C., and Tomás-Barberán, F. A. (2016). Chromatographic and spectroscopic characterization of urolithins for their determination in biological samples after the intake of foods containing ellagitannins and ellagic acid. J. Chromatogr. A 1428, 162-175. doi: 10.1016/j.chroma.2015.08.044
13. García-Villalba, R., Vissenaekens, H., Pitart, J., Romo-Vaquero, M., Espín, J. C., Grootaert, C., et al. (2017). The gastrointestinal simulation model TWINSHIME shows differences between human urolithin-metabotypes in gut microbiota composition, pomegranate polyphenol metabolism, and transport along the intestinal tract. J. Agric. Food Chem. 65, 5480-5493. doi: 10.1021/acs. jafc.7b02049
14. González-Sarrías, A., García-Villalba, R., Romo-Vaquero, M., Alasalvar, C., Orem, A., Zafrilla, P., et al. (2016). Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: A randomised clinical trial. Mol. Nutr. Food Res. 61:1600830. doi: 10.1002/mnfr. 201600830
15. González-Sarrías, A., Giménez-Bastida, J. A., García-Conesa, M. T., Gómez-Sánchez, M. B., García-Talavera, N. V., Gil-Izquierdo, A., et al. (2010). Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol. Nutr. Food Res. 54, 311-322. doi: 10.1002/mnfr.200900152
16. González-Sarrías, A., Nuñez-Sánchez, M. A., García-Villalba, R., Tomás-Barberán, F. A., and Espín, J. C. (2017). Antiproliferative activity of the ellagic acid-derived gut microbiota isourolithin A and comparison with its urolithin A isomer: the role of cell metabolism. Eur. J. Nutr. 56, 831-841.
17. Gupta, R. S., Chen, W. J., Adeolu, M., and Chai, Y. (2013). Molecular signatures for the class Coriobacteriia and its different clades; proposal for division of the class Coriobacteriia into the emended order Coriobacteriales, containing the emended family Coriobacteriaceae and Atopobiaceae fam. nov., and Eggerthe. Int. J. Syst. Evol. Microbiol. 63, 3379-3397. doi: 10.1099/ijs.0.048371-0
18. Jukes, T. H., and Cantor, C. R. (1969). Evolution of Protein Molecules. New York, NY: Academic Press, 21-132.
19. Kumar, S., Stecher, G., and Tamura, K. (2016). MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 33, 1870-1874. doi: 10.1093/molbev/msw054
20. Larrosa, M., García-Conesa, M. T., Espín, J. C., and Tomás-Barberán, F. A. (2010). Ellagitannins, ellagic acid and vascular health. Mol. Aspects Med. 31, 513-539. doi: 10.1016/j.mam.2010.09.005
21. Lucena, T., Pascual, J., Garay, E., Arahal, D. R., Macián, M. C., and Pujalte, M. J. (2010). Haliea mediterranea sp. nov., a marine gammaproteobacterium. Int. J. Syst. Evol. Microbiol. 60, 1844-1848. doi: 10.1099/ijs.0.017061-0
22. Matthies, A., Clavel, T., Gutschow, M., Engst, W., Haller, D., Blaut, M., et al. (2008). Conversion of daidzein and genistein by an anaerobic bacterium newly isolated from the mouse intestine. Appl. Environ. Microbiol. 74, 4847-4852. doi: 10.1128/AEM.00555-08
23. Nuñez-Sánchez, M. A., García-Villalba, R., Monedero-Saiz, T., García-Talavera, N. V., Gómez-Sánchez, M. B., Sánchez-álvarez, C., et al. (2014). Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol. Nutr. Food Res. 58, 1199-1211. doi: 10.1002/mnfr.201300931
24. Romo-Vaquero, M., García-Villalba, R., González-Sarrías, A., Beltrán, D., Tomás-Barberán, F. A., Espín, J. C., et al. (2015). Interindividual variability in the human metabolism of ellagic acid: contribution of Gordonibacter to urolithin production. J. Funct. Foods 17, 785-791. doi: 10.1016/j.jff.2015.06.040
25. Selma, M. V., González-Sarrías, A., Salas-Salvadó, J., Andrés-Lacueva, C., Alasalvar, C., Orem, A., et al. (2016). The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: comparison between normoweight, overweight-obesity and metabolic syndrome. Clin. Nutr. 17, 30103-30106. doi: 10.1016/j.clnu.2017.03.012
26. Selma, M. V., Romo-Vaquero, M.,García-Villalba, R., González-Sarrías, A., Tomás-Barberán, F. A., and Espín, J. C. (2015). The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism. Food Funct. 7, 1769-1774. doi: 10.1039/c5fo01100k
27. Selma, M. V., Tomas-Barberan, F. A., Beltran, D., García-Villalba, R., and Espin, J. C. (2014a). Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. Int. J. Syst. Evol. Microbiol. 64, 2346-2352. doi: 10.1099/ijs.0.055095-0
28. Selma, M. V., Beltrán, D., García-Villalba, R., Espín, J. C., and Tomás-Barberán, F. A. (2014b). Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. 5, 1779-1784. doi: 10.1039/c4fo00092g
29. Stackebrandt, E., and Goebel, B. M. (1994). Taxonomic note: a place for DNA-DNA reassociation and 16S rRNA sequence analysis in the present species definition in bacteriology. Int. J. Syst. Bacteriol. 44, 846-849.
30. Thawornkuno, C., Tanaka, M., Sone, T., and Asano, K. (2009). Biotransformation of daidzein to equol by crude enzyme from Asaccharobacter celatus AHU1763 required an anaerobic environment. Biosci. Biotechnol. Biochem. 73, 1435-1438. doi: 10.1271/bbb.80908
31. Tomás-Barberán, F. A., García-Villalba, R., González-Sarrías, A., Selma, M. V., and Espín, J. C. (2014). Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J. Agric. Food Chem. 62, 6535-6538. doi: 10.1021/jf5024615
32. Tomás-Barberán, F. A., González-Sarrías, A., García-Villalba, R., Núñez-Sánchez, M. A., Selma, M. V., García-Conesa, M. T., et al. (2016a). Urolithins, the rescue of "old" metabolites to understand a "new" concept: metabotypes as a nexus between phenolic metabolism, microbiota dysbiosis and host health status. Mol. Nutr. Food Res. 61, 1-74. doi: 10.1002/mnfr.20150 0901
33. Tomás-Barberán, F. A., Selma, M. V., and Espín, J. C. (2016b). Interactions of gut microbiota with dietary polyphenols and consequences to human health. Curr. Opin. Clin. Nutr. Metab. Care 19, 471-476. doi: 10.1097/MCO. 0000000000000314